-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 13, China Pharmaceuticals announced that recently, Hainan General Sanyo, a wholly-owned subsidiary of the company, obtained three "Approval Notices for Supplementary Application of Drugs for Ceftazidime" approved and issued by the State Food and Drug Administration.
It is understood that ceftazidime for injection belongs to the third-generation cephalosporin antibiotic.
Ceftazidime for injection was developed by GlaxoSmithKline.
(2) The State Food and Drug Administration will accept the application for consistency evaluation of the drug in May 2020.
(3) As of the disclosure date of this announcement, the investment in the research and development of the drug was approximately RMB 7.
(4) According to the website of the State Food and Drug Administration, as of the disclosure date of this announcement, 10 domestic manufacturers including General Sanyo have passed the consistency evaluation of the drug.
(5) According to the query data from Zhongkang, the domestic sales of ceftazidime for injection in 2020 will be approximately 2.